328 related articles for article (PubMed ID: 34118929)
1. Targeting S100A4 with niclosamide attenuates inflammatory and profibrotic pathways in models of amyotrophic lateral sclerosis.
Milani M; Mammarella E; Rossi S; Miele C; Lattante S; Sabatelli M; Cozzolino M; D'Ambrosi N; Apolloni S
J Neuroinflammation; 2021 Jun; 18(1):132. PubMed ID: 34118929
[TBL] [Abstract][Full Text] [Related]
2. The S100A4 Transcriptional Inhibitor Niclosamide Reduces Pro-Inflammatory and Migratory Phenotypes of Microglia: Implications for Amyotrophic Lateral Sclerosis.
Serrano A; Apolloni S; Rossi S; Lattante S; Sabatelli M; Peric M; Andjus P; Michetti F; Carrì MT; Cozzolino M; D'Ambrosi N
Cells; 2019 Oct; 8(10):. PubMed ID: 31623154
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective effects of niclosamide on disease progression via inflammatory pathways modulation in SOD1-G93A and FUS-associated amyotrophic lateral sclerosis models.
Milani M; Della Valle I; Rossi S; Fabbrizio P; Margotta C; Nardo G; Cozzolino M; D'Ambrosi N; Apolloni S
Neurotherapeutics; 2024 Apr; 21(3):e00346. PubMed ID: 38493058
[TBL] [Abstract][Full Text] [Related]
4. S100A4 drives non-small cell lung cancer invasion, associates with poor prognosis, and is effectively targeted by the FDA-approved anti-helminthic agent niclosamide.
Stewart RL; Carpenter BL; West DS; Knifley T; Liu L; Wang C; Weiss HL; Gal TS; Durbin EB; Arnold SM; O'Connor KL; Chen M
Oncotarget; 2016 Jun; 7(23):34630-42. PubMed ID: 27127879
[TBL] [Abstract][Full Text] [Related]
5. S100a4 Is Secreted by Alternatively Activated Alveolar Macrophages and Promotes Activation of Lung Fibroblasts in Pulmonary Fibrosis.
Zhang W; Ohno S; Steer B; Klee S; Staab-Weijnitz CA; Wagner D; Lehmann M; Stoeger T; Königshoff M; Adler H
Front Immunol; 2018; 9():1216. PubMed ID: 29910813
[TBL] [Abstract][Full Text] [Related]
6. Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis.
Verbeeck C; Deng Q; Dejesus-Hernandez M; Taylor G; Ceballos-Diaz C; Kocerha J; Golde T; Das P; Rademakers R; Dickson DW; Kukar T
Mol Neurodegener; 2012 Oct; 7():53. PubMed ID: 23046583
[TBL] [Abstract][Full Text] [Related]
7. Elevation of S100A4 expression in buccal mucosal fibroblasts by arecoline: involvement in the pathogenesis of oral submucous fibrosis.
Yu CC; Tsai CH; Hsu HI; Chang YC
PLoS One; 2013; 8(1):e55122. PubMed ID: 23383075
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological Inhibition of S100A4 Attenuates Fibroblast Activation and Renal Fibrosis.
Wen J; Jiao B; Tran M; Wang Y
Cells; 2022 Sep; 11(17):. PubMed ID: 36078170
[TBL] [Abstract][Full Text] [Related]
9. Effect of Anti-S100A4 Monoclonal Antibody Treatment on Experimental Skin Fibrosis and Systemic Sclerosis-Specific Transcriptional Signatures in Human Skin.
Trinh-Minh T; Györfi AH; Tomcik M; Tran-Manh C; Zhou X; Dickel N; Tümerdem BS; Kreuter A; Burmann SN; Borchert SV; Hussain RI; Hallén J; Klingelhöfer J; Kunz M; Distler JHW
Arthritis Rheumatol; 2024 May; 76(5):783-795. PubMed ID: 38108109
[TBL] [Abstract][Full Text] [Related]
10. From Mouse Models to Human Disease: An Approach for Amyotrophic Lateral Sclerosis.
Alrafiah AR
In Vivo; 2018; 32(5):983-998. PubMed ID: 30150420
[TBL] [Abstract][Full Text] [Related]
11. ALS-causing mutations differentially affect PGC-1α expression and function in the brain vs. peripheral tissues.
Bayer H; Lang K; Buck E; Higelin J; Barteczko L; Pasquarelli N; Sprissler J; Lucas T; Holzmann K; Demestre M; Lindenberg KS; Danzer KM; Boeckers T; Ludolph AC; Dupuis L; Weydt P; Witting A
Neurobiol Dis; 2017 Jan; 97(Pt A):36-45. PubMed ID: 27818323
[TBL] [Abstract][Full Text] [Related]
12. ALS mutations of FUS suppress protein translation and disrupt the regulation of nonsense-mediated decay.
Kamelgarn M; Chen J; Kuang L; Jin H; Kasarskis EJ; Zhu H
Proc Natl Acad Sci U S A; 2018 Dec; 115(51):E11904-E11913. PubMed ID: 30455313
[TBL] [Abstract][Full Text] [Related]
13. Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer.
Sack U; Walther W; Scudiero D; Selby M; Kobelt D; Lemm M; Fichtner I; Schlag PM; Shoemaker RH; Stein U
J Natl Cancer Inst; 2011 Jul; 103(13):1018-36. PubMed ID: 21685359
[TBL] [Abstract][Full Text] [Related]
14. Molecular and behavioural abnormalities in the FUS-tg mice mimic frontotemporal lobar degeneration: Effects of old and new anti-inflammatory therapies.
de Munter J; Babaevskaya D; Wolters EC; Pavlov D; Lysikova E; V Kalueff A; Gorlova A; Oplatchikova M; Pomytkin IA; Proshin A; Umriukhin A; Lesch KP; Strekalova T
J Cell Mol Med; 2020 Sep; 24(17):10251-10257. PubMed ID: 32667139
[TBL] [Abstract][Full Text] [Related]
15. MTOR-independent, autophagic enhancer trehalose prolongs motor neuron survival and ameliorates the autophagic flux defect in a mouse model of amyotrophic lateral sclerosis.
Zhang X; Chen S; Song L; Tang Y; Shen Y; Jia L; Le W
Autophagy; 2014 Apr; 10(4):588-602. PubMed ID: 24441414
[TBL] [Abstract][Full Text] [Related]
16. Disrupted autophagy and neuronal dysfunction in C. elegans knockin models of FUS amyotrophic lateral sclerosis.
Baskoylu SN; Chapkis N; Unsal B; Lins J; Schuch K; Simon J; Hart AC
Cell Rep; 2022 Jan; 38(4):110195. PubMed ID: 35081350
[TBL] [Abstract][Full Text] [Related]
17. Mutation analysis of SOD1, C9orf72, TARDBP and FUS genes in ethnically-diverse Malaysian patients with amyotrophic lateral sclerosis (ALS).
Edgar S; Ellis M; Abdul-Aziz NA; Goh KJ; Shahrizaila N; Kennerson ML; Ahmad-Annuar A
Neurobiol Aging; 2021 Dec; 108():200-206. PubMed ID: 34404558
[TBL] [Abstract][Full Text] [Related]
18. Mutations in the 3' untranslated region of FUS causing FUS overexpression are associated with amyotrophic lateral sclerosis.
Sabatelli M; Moncada A; Conte A; Lattante S; Marangi G; Luigetti M; Lucchini M; Mirabella M; Romano A; Del Grande A; Bisogni G; Doronzio PN; Rossini PM; Zollino M
Hum Mol Genet; 2013 Dec; 22(23):4748-55. PubMed ID: 23847048
[TBL] [Abstract][Full Text] [Related]
19. Comparative interactomics analysis of different ALS-associated proteins identifies converging molecular pathways.
Blokhuis AM; Koppers M; Groen EJN; van den Heuvel DMA; Dini Modigliani S; Anink JJ; Fumoto K; van Diggelen F; Snelting A; Sodaar P; Verheijen BM; Demmers JAA; Veldink JH; Aronica E; Bozzoni I; den Hertog J; van den Berg LH; Pasterkamp RJ
Acta Neuropathol; 2016 Aug; 132(2):175-196. PubMed ID: 27164932
[TBL] [Abstract][Full Text] [Related]
20. Oxr1 improves pathogenic cellular features of ALS-associated FUS and TDP-43 mutations.
Finelli MJ; Liu KX; Wu Y; Oliver PL; Davies KE
Hum Mol Genet; 2015 Jun; 24(12):3529-44. PubMed ID: 25792726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
